Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Investigational

4

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Tyrosine-protein kinase JAK1

4

Tyrosine-protein kinase JAK2

4

Tyrosine-protein kinase JAK3

4

Tyrosine-protein kinase TYK2

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase III

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

4

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Crohn's disease

4

Rheumatoid arthritis

4

Ulcerative colitis

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

4

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Galapagos

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

EVMPD

4

FDA UNII

4

PUBCHEM

4

SMS_ID

4

CAS

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

FILGOTINIB

3XVL385Q0M

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Tyrosine-protein kinase JAK1

Tyrosine-protein kinase JAK2

Tyrosine-protein kinase JAK3

Tyrosine-protein kinase TYK2

Conditions:

Crohn's disease

Rheumatoid arthritis

Ulcerative colitis

Filgotinib (GLPG0634) is a highly selective JAK1 inhibitor. GLPG0634 is a promising drug candidate for the future treatment of autoimmune and inflammatory disorders. It is in phase III clinical trials (initiated mid-2016) for the treatment of rheumat...

oid arthritis, Crohn's disease and ulcerative colitis. Most common adverse events observed were infections, gastrointestinal disorders and nervous system disorders.

FILGOTINIB MALEATE

JG8OB4UL9Y

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Tyrosine-protein kinase JAK1

Tyrosine-protein kinase JAK2

Tyrosine-protein kinase JAK3

Tyrosine-protein kinase TYK2

Conditions:

Crohn's disease

Rheumatoid arthritis

Ulcerative colitis

Filgotinib (GLPG0634) is a highly selective JAK1 inhibitor. GLPG0634 is a promising drug candidate for the future treatment of autoimmune and inflammatory disorders. It is in phase III clinical trials (initiated mid-2016) for the treatment of rheumat...

oid arthritis, Crohn's disease and ulcerative colitis. Most common adverse events observed were infections, gastrointestinal disorders and nervous system disorders.

FILGOTINIB HYDROCHLORIDE

2CQ8Y0B8XQ

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Tyrosine-protein kinase JAK1

Tyrosine-protein kinase JAK2

Tyrosine-protein kinase JAK3

Tyrosine-protein kinase TYK2

Conditions:

Crohn's disease

Rheumatoid arthritis

Ulcerative colitis

Filgotinib (GLPG0634) is a highly selective JAK1 inhibitor. GLPG0634 is a promising drug candidate for the future treatment of autoimmune and inflammatory disorders. It is in phase III clinical trials (initiated mid-2016) for the treatment of rheumat...

oid arthritis, Crohn's disease and ulcerative colitis. Most common adverse events observed were infections, gastrointestinal disorders and nervous system disorders.

FILGOTINIB HYDROCHLORIDE ANHYDROUS

465AWI19JW

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Tyrosine-protein kinase JAK1

Tyrosine-protein kinase JAK2

Tyrosine-protein kinase JAK3

Tyrosine-protein kinase TYK2

Conditions:

Crohn's disease

Rheumatoid arthritis

Ulcerative colitis

Filgotinib (GLPG0634) is a highly selective JAK1 inhibitor. GLPG0634 is a promising drug candidate for the future treatment of autoimmune and inflammatory disorders. It is in phase III clinical trials (initiated mid-2016) for the treatment of rheumat...

oid arthritis, Crohn's disease and ulcerative colitis. Most common adverse events observed were infections, gastrointestinal disorders and nervous system disorders.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1